問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Ophthalmology

更新時間：2023-09-19

林怡嬋Lin, I-Chan
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林怡嬋

List

2Cases

2021-03-16 - 2029-12-31

Phase III

Active
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

  • Condition/Disease

    AZD9833 AZD9833 is being developed for treatment of ER-positive, HER2-negative breast cancer. Anastrozole Arimidex is indicated for the: -Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. -Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women. -Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen. Palbociclib IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: -in combination with an aromatase inhibitor; -in combination with fulvestrant in women who have received prior endocrine therapy (see section 5.1). In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

  • Test Drug

    AZD9833 ArimidexR IbranceR

Participate Sites
10Sites

Recruiting9Sites

Terminated1Sites

2021-06-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting9Sites

Recruiting2Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB